Skip to main content
. Author manuscript; available in PMC: 2021 Sep 15.
Published in final edited form as: Eur J Pharmacol. 2020 Jul 11;883:173362. doi: 10.1016/j.ejphar.2020.173362

Fig.3-. Differential regulation of the expression of total Nrxn1 and 3 and their alternative splicing in NAc after CVS.

Fig.3-

(A-C) Real-time PCR quantification of total Nrxn1/3 and alternative splicing variants (splicing site 4, SS4) in male stressed mice with or without DHCA treatment. Fold change of (A) Nrxn1 and Nrxn3 total mRNA (B) Nrxn3 SS4+ and SS43− mRNA and (C) Nrxn1 SS4+ and SS4− mRNA in stressed male mice with or without treatment relative to the non -stressed control mice (vehicle). (D-F) Real-time PCR quantification of total Nrxn1/3 and alternative splicing variants (splicing site 4, SS4) in female stressed mice with or without DHCA treatment. Fold change of (D) Nrxn1 and Nrxn3 total mRNA (E) Nrxn3 SS4+ and SS43− mRNA and (F) Nrxn1 SS4+ and SS4− mRNA in stressed female mice with or without treatment relative to non -stressed control mice (vehicle). Female mice, One-way ANOVA: F 3,40= 13.68 , P < 0.0001 for NRX1; F 3,36 = 3.42 , P = 0.023 for Nrxn1 SS4+; F 3, 35 = 0.44, P= 0,72 for Nrxn1 SS4−; F 3,40 = 7.45 , P = 0.0001 for Nrxn3; F 3,39 = 10.66, P < 0.0001 for Nrxn3 SS4+; F 3, 38 = 3.911, P = 0.0123 for Nrxn3 SS4−. Male mice, One-way ANOVA: F 3,36 =10.49, P <0.001 for NRX1; F 3,39 =6.253 , P= 0.0011 for Nrxn1 SS4+ ; F 3,37 = 1.72, P= 0.170 for Nrxn1 SS4−; F 3,34 =2.162, P=0.195 for Nrxn3; F 3,38 =2.062, P= 0.3915 for Nrxn3 SS4+; F 3,34= 0.91, P= 0.40 for Nrxn3 SS4−). Nrxn mRNA values were normalized vs GADPH as internal control and expressed as fold changes relative to non-treated controls (vehicle). Bar graphs represents Mean ± S.E.M. ( *P <0.05; **P <0.01; ***P <0.001; n=8-10 animals/group).